Peter V. Danenberg
Affiliations: | University of Southern California, Los Angeles, CA, United States |
Area:
Biostatistics Biology, Genetics, Molecular BiologyGoogle:
"Peter Danenberg"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Raez LE, Danenberg K, Sumarriva D, et al. (2021) Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors. Cancer Drug Resistance (Alhambra, Calif.). 4: 1061-1071 |
| Hodara E, Morrison G, Cunha AT, et al. (2019) Multi-parametric liquid biopsy analysis in metastatic prostate cancer. Jci Insight |
| Sunakawa Y, Usher JL, Jaimes YS, et al. (2019) Clinical verification of circulating tumor RNA (ctRNA) as novel pretreatment predictor and tool for quantitative monitoring of treatment response in metastatic colorectal cancer (mCRC): A biomarker study of the DEEPER trial. Journal of Clinical Oncology. 37 |
| Raez LE, Usher JL, Danenberg K, et al. (2019) RNA-based biomarker signatures in plasma as an independent predictor of outcome to chemotherapy in lung, colon, and breast cancers: Correlation of relative PD-L1 expression with immunotherapy outcomes. Journal of Clinical Oncology. 37 |
| Raez L, Usher J, Danenberg K, et al. (2019) P1.01-68 Monitoring Clinical Responses Measuring PD-L1 in cfRNA in Plasma of Non-Small Cell Lung Cancer Patients Undergoing Systemic Therapy Journal of Thoracic Oncology. 14 |
| Sunakawa Y, Usher J, Satake H, et al. (2018) Gene mutation status in circulating tumor DNA (ctDNA) and first-line FOLFOXIRI plus bevacizumab (bev) in metastatic colorectal cancer (mCRC) harboring RAS mutation. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii181-viii182 |
| Ishiba T, Hoffmann AC, Usher J, et al. (2018) Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types. Biochemical and Biophysical Research Communications |
| Kollengode KA, Grussie E, Danenberg G, et al. (2018) Immune checkpoint molecule expression measured using circulating cell-free RNA isolated from the blood of metastatic prostate cancer patients. Journal of Clinical Oncology. 36: 380-380 |
| Hodara E, Zainfeld D, Morrison G, et al. (2018) Multi-parametric liquid biopsy analysis of circulating tumor cells (CTCs), cell-free DNA (cfDNA), and cell-free RNA (cfRNA) in metastatic castrate resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 274-274 |
| Grussie E, Danenberg G, Kollengode KA, et al. (2018) Gene expression differences in cell-free RNA between prostate cancer patients and healthy individuals. Journal of Clinical Oncology. 36 |